FLEMINGTON, N.J.--(BUSINESS WIRE)--NovaDel Pharma Inc. (AMEX: NVD) today announced positive results from a pharmacokinetic study of its improved oral spray formulation of sumatriptan, the active ingredient in GlaxoSmithKline’s leading migraine remedy, Imitrex®.
